Who are ropivacaine,morphine chloride,epinephrine,ketorolac's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropivacaine-morphine-chloride-epinephrine-ketorolac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ropivacaine,morphine chloride,epinephrine,ketorolac — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ropivacaine,morphine chloride,epinephrine,ketorolac (ropivacaine,morphine chloride,epinephrine,ketorolac) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic). Area: Pain Management

marketed Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac) Pain Management / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ropivacaine,morphine chloride,epinephrine,ketorolac (ropivacaine,morphine chloride,epinephrine,ketorolac) — Jose Antonio Bernia Gil. This is a combination analgesic and anesthetic formulation that blocks nerve conduction (ropivacaine), activates opioid receptors (morphine), increases sympathetic tone (epinephrine), and inhibits prostaglandin synthesis (ketorolac) to provide multimodal pain relief and local anesthesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ropivacaine,morphine chloride,epinephrine,ketorolac TARGET	ropivacaine,morphine chloride,epinephrine,ketorolac	Jose Antonio Bernia Gil	marketed	Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)	Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) class)

Jose Antonio Bernia Gil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ropivacaine,morphine chloride,epinephrine,ketorolac — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-morphine-chloride-epinephrine-ketorolac. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab